Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases
<p><strong>Background & Aims</strong> Gut-homing lymphocytes that express the integrin α4β7 and CCR9 might contribute to development of primary sclerosing cholangitis (PSC). Vedolizumab, which blocks the integrin α4β7, is used to treat patients with inflammatory bowel disea...
Үндсэн зохиолчид: | Lynch, K, Chapman, R, Keshav, S, Montano-Loza, A, Mason, A, Kremer, A, Vetter, M, De Krijger, M, Ponsioen, C, Trivedi, P, Hirschfield, G, Schramm, C, Liu, C, Bowlus, C, Estes, D, Pratt, D, Hedin, C, Bergquist, A, De Vries, A, Janneke Van Der Woude, C, Yu, L, Assis, D, Boyer, J, Ytting, H, Hallibasic, E, Trauner, M, Marschall, H, Daretti, L, Marzioni, M, Yimam, K, Perin, N, Floreani, A, Beretta-Piccoli, B, Rogers, J, International Primary Sclerosing Cholangitis Study Group (IPSCSG), Levy, C |
---|---|
Формат: | Journal article |
Хэл сонгох: | English |
Хэвлэсэн: |
Elsevier
2019
|
Ижил төстэй зүйлс
Ижил төстэй зүйлс
-
International experience of vedolizumab in primary sclerosing cholangitis and inflammatory bowel disease
-н: Williamson, K, зэрэг
Хэвлэсэн: (2018) -
Vedolizumab for the treatment of chronic pouchitis
-н: Travis, S, зэрэг
Хэвлэсэн: (2023) -
Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease
-н: Renske W. M. Pauwels, зэрэг
Хэвлэсэн: (2020-12-01) -
Subcutaneous vedolizumab interval extension in inflammatory bowel disease patients: a case series
-н: Suzanne I. Anjie, зэрэг
Хэвлэсэн: (2024-02-01) -
Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases
-н: Matthew Luzentales-Simpson, зэрэг
Хэвлэсэн: (2021-02-01)